BRIEF—Younger EU patients to get asthma drug

The European Medicines Agency (EMA) has approved flutiform (pMDI 50/5 µg) for twice-daily use in the treatment of children with asthma aged five years and over.

Napp Pharmaceuticals is now able to offer the drug to this younger age group, it having been available for patients aged 12 years and above since 2012.

This new pediatric licence provides for a regular asthma maintenance treatment option, with a dose of two puffs 50/5 µg twice-daily, in children aged five years and over, when a combination of an inhaled corticosteroid and a long-acting β2-agonist is appropriate.